Dongsung Pharmaceutical's first group status disclosure after Taekwang affiliation: 620% debt ratio and 10.1B KRW operating loss highlight need for restructuring despite rehabilitation completion
Annual group status disclosure for Dongsung Pharmaceutical, a member of Taekwang group, as of May 29, 2026
As of FY2025 (Dec 31, 2025): Assets 168.4B KRW, Liabilities 145.1B KRW, Equity 23.4B KRW, Debt ratio 620.7% indicating weak financial health
Revenue 87.2B KRW, operating loss 10.1B KRW, net loss 25.7B KRW, continued profitability deterioration
Major shareholder: Uamco Pharmaceutical PEF (41.40%), related party Taekwang Industrial (31.05%), treasury shares 2.29%
Rehabilitation procedure concluded on May 15, 2026; new CEO Choi Yong-seok appointed, management overhauled
All outside directors are newly appointed, board committees (audit, ethics, etc.) established for governance improvement
[AI Summary]Dongsung Pharmaceutical has secured legal stability through Taekwang group affiliation and rehabilitation closure, but the high debt ratio of 620% and net loss of 25.7B KRW pose long-term hurdles to restoring shareholder value
KOSPI Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]